Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 13/20 | 0.47 |
| ▸ | CTSS | P25774 | 13/20 | 0.47 |
| ▸ | CTSL | P07711 | 4/20 | 0.44 |
| ▸ | CTSB | P07858 | 3/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26110455 | 0.87 | CTSS (0.50) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL2719723 | 0.87 | CTSS (0.50) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL26110452 | 0.87 | CTSS (0.50) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL165351 | 0.87 | CYP2D6 (0.53) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL165350 | 0.87 | CYP2D6 (0.53) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL15259348 | 0.83 | CTSK (0.56) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL5958657 | 0.83 | CTSK (0.56) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL28668864 | 0.81 | CYP1A2 (0.49) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL28668862 | 0.81 | CYP1A2 (0.49) | CTSKCTSSCTSLCTSBCA1 | |
| SCHEMBL18762484 | 0.81 | CTSK (0.48) | CTSKCTSSCTSLCTSBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741927-B2 | Production method of intermediate compound for synthesizing medicament | LG LIFE SCIENCES LTD. (KR) | 2014-06-03 | — | — | US | disclosed |
| US-20130165659-A1 | PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT | LG LIFE SCIENCES LTD. (KR) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165659-A1 | PRODUCTION METHOD OF INTERMEDIATE COMPOUND FOR SYNTHESIZING MEDICAMENT | DPP4, DPP7, DPP8 | CTSK 272/4885CTSS 437/4885CTSL 111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.